Glanzmann Thrombasthenia (GT)
Gene or Region: ITGA2B
Reference Variant: G, 10bp indel (GACAGGTGAG)
Mutant Variant: C, - (deletion)
Affected Breeds: Thoroughbred, Standardbred, Oldenburg, Peruvian Paso, American Paint Horse, Appaloosa and American Quarter Horse
Research Confidence: Discovery - Findings require expanded validation
Explanation of Results: GT/GT = homozygous for Glanzmann Thrombasthenia, trait expressed GT/n = heterozygous for Glanzmann Thrombasthenia, trait possibly expressed n/n = no variant detected
General Description
Glanzmann Thrombasthenia (GT) is an inherited platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings. Two mutations in the gene encoding platelet glycoprotein IIb, Integrin Alpha-2B (ITGA2B), have been implicated in the GT condition. Although GT has been associated with a recessive mode of inheritance, heterozygous combinations from both variants have been implicated in GT cases. GT can be a differential diagnosis for horses with platelet-type bleeding, especially nasal bleeding not related to exercise or of unknown origin (not thrombocytopenic or from von Willebrand disease).
Genotype
G/G and/or GACAGGTGAG/GACAGGTGAG: No variants - Negative for the known genetic factors of Glanzmann Thrombasthenia (GT). Horse may still have Glanzmann Thrombasthenia (GT) signs from novel/unknown mutations.
G/C or GACAGGTGAG: One allele (at either locus) - Horse is a carrier for Glanzmann Thrombasthenia (GT). Selective breeding is advised as to not produce homozygous or compound heterozygous offspring.
G/C and GACAGGTGAG/- ; or C/C ; or -/-: Two alleles (at either locus) - Horse is affected by Glanzmann Thrombasthenia (GT). Please consult with your attending veterinarian about management for this condition.
References
Christopherson, P.W., van Santen, V.L., Livesey, L. and Boudreaux, M.K. (2007), A 10-Base-Pair Deletion in the Gene Encoding Platelet Glycoprotein IIb Associated with Glanzmann Thrombasthenia in a Horse. Journal of Veterinary Internal Medicine, 21: 196-198. https://doi.org/10.1111/j.1939-1676.2007.tb02947.x
Christopherson PW, Insalaco TA, Santen VL van, Livesey L, Bourne C, Boudreaux MK. Characterization of the cDNA Encoding αIIb and β3 in Normal Horses and Two Horses with Glanzmann Thrombasthenia. Veterinary Pathology. 2006;43(1):78-82. doi:10.1354/vp.43-1-78
More Horse Health
Recurrent Laryngeal Neuropathy
Recurrent Laryngeal Neuropathy (RLN) is a disease that results in loss of the neurons that open the larynx, significantly affecting performance in Thoroughbreds and other sport horses. It is an important issue for horses in competitive events because the resultant paralysis of the larynx leads to obstruction of air flow during intense exercise, creating the abnormal inspiratory noise that gives RLN its common name: “roaring”.
Severe Combined Immunodeficiency
Severe Combined Immunodeficiency Disease (SCID) is a condition in which affected foals are unable to mount an effective immune response after infection and are unable to recover from infections that unaffected foals would easily resist. The disease is universally fatal in horses, usually within 4-6 months of life.
West Nile Virus Symptom Susceptibility / Risk
West Nile Virus (WNV) is a mosquito-borne virus that can infect multiple types of mammals, including horses. Infection can lead to a series of severe symptoms, most commonly encephalitis – acute inflammation of the brain. Severe neurological symptoms develop in ~8% of exposed horses, and once symptoms manifest, the fatality rate ranges from 20-40% and is higher in older horses.